Arcutis Biotherapeutics, Inc.

Equities

ARQT

US03969K1088

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-23 pm EDT			5-day change	1st Jan Change
9.08 ^USD	-8.47%		-1.73%	+181.11%

May. 15	Needham Adjusts Price Target on Arcutis Biotherapeutics to $18 From $16, Maintains Buy Rating	MT
May. 15	Sector Update: Health Care Stocks Rise Pre-Bell Wednesday	MT

Arcutis Biotherapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023

February 27, 2024 at 05:50 am EST

Arcutis Biotherapeutics, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported revenue was USD 13.53 million compared to USD 2.96 million a year ago. Net loss was USD 66.28 million compared to USD 72.02 million a year ago. Basic loss per share from continuing operations was USD 0.72 compared to USD 1.18 a year ago.
For the full year, revenue was USD 59.61 million compared to USD 3.69 million a year ago. Net loss was USD 262.14 million compared to USD 311.46 million a year ago. Basic loss per share from continuing operations was USD 3.78 compared to USD 5.66 a year ago.

Latest news about Arcutis Biotherapeutics, Inc.

Needham Adjusts Price Target on Arcutis Biotherapeutics to $18 From $16, Maintains Buy Rating	May. 15	MT
Sector Update: Health Care Stocks Rise Pre-Bell Wednesday	May. 15	MT
Sector Update: Health Care	May. 15	MT
Mizuho Securities Adjusts Arcutis Biotherapeutics Price Target to $18 From $17, Maintains Buy Rating	May. 15	MT
Arcutis Biotherapeutics Q1 Loss Narrows as Revenue Surges; Shares Soar Premarket	May. 15	MT
Arcutis Biotherapeutics Q1 Loss Narrows, Revenue Increases; Shares Jump	May. 14	MT
Transcript : Arcutis Biotherapeutics, Inc., Q1 2024 Earnings Call, May 14, 2024	May. 14
Arcutis Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 14	CI
Earnings Flash (ARQT) ARCUTIS BIOTHERAPEUTICS Posts Q1 Revenue $49.6M	May. 14	MT
Arcutis Biotherapeutics, Inc. Announces Chief Financial Officer Changes	Apr. 10	CI
Arcutis Biotherapeutics, Inc.(NasdaqGS:ARQT) added to S&P Biotechnology Select Industry Index	Mar. 17	CI
Arcutis Promotes Todd Tucker to Chief Human Resources Officer	Mar. 11	CI
Arcutis Biotherapeutics Says Atopic Dermatitis Cream Met Primary Endpoint in Phase 3 Study in Children	Mar. 11	MT
Arcutis Presents Late-Breaking Data from INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 At the American Academy of Dermatology Annual Meeting	Mar. 10	CI
Arcutis Biotherapeutics Raises $172.5 Million in Common Stock Offering	Mar. 04	MT
Arcutis Plans $150 Million Offering, Signs Collaboration, Licensing Deal for Roflumilast in Japan; Shares Fall After Hours	Feb. 28	MT
Mizuho Securities Raises Price Target on Arcutis Biotherapeutics to $17 From $16, Maintains Buy Rating	Feb. 28	MT
Needham Raises Price Target on Arcutis Biotherapeutics to $16 From $8, Maintains Buy Rating	Feb. 28	MT
Transcript : Arcutis Biotherapeutics, Inc., Q4 2023 Earnings Call, Feb 27, 2024	Feb. 27
North American Morning Briefing : Stock Futures Pause as Investors Eye Inflation Data	Feb. 27	DJ
Earnings Flash (ARQT) ARCUTIS BIOTHERAPEUTICS Posts Q4 Revenue $13.5M, vs. Street Est of $11.4M	Feb. 27	MT
Arcutis Biotherapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 27	CI
Mizuho Increases Price Target on Arcutis Biotherapeutics to $16 From $8, Maintains Buy Rating	Feb. 23	MT
Arcutis Biotherapeutics, Inc. Announces Publication of Positive Results from the Pivotal Phase 3 Trial Evaluating ZORYVE (roflumilast) Foam	Jan. 29	CI
Transcript : Arcutis Biotherapeutics, Inc. - Special Call	Jan. 22

Chart Arcutis Biotherapeutics, Inc.

Duration

Period

More charts

Company Profile

Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. ZORYVE cream is a once-daily topical formulation of roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor. The Companyâs pipeline includes ARQ-255, ARQ-252, and ARQ-234. ARQ-255 is developed for alopecia areata. ARQ-252 is an alternative topical cream formulation of ivarmacitinib that the Company is developing for chronic hand eczema and vitiligo. ARQ-255 is developed for the treatment of alopecia areata.

Sector

Biotechnology & Medical Research

Calendar

2024-07-31 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Arcutis Biotherapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

9.92 USD

Average target price

19 USD

Spread / Average Target

+91.53%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ARCUTIS BIOTHERAPEUTICS, INC.	+181.11%	1.15B
VERTEX PHARMACEUTICALS INCORPORATED	+10.79%	115B
REGENERON PHARMACEUTICALS, INC.	+11.65%	106B
BIONTECH SE	-6.20%	24.69B
ARGENX SE	-2.33%	21.97B
GENMAB A/S	-6.03%	19.27B
BEIGENE, LTD.	-13.41%	17.56B
WUXI APPTEC CO., LTD.	-40.50%	17.32B
NEUROCRINE BIOSCIENCES, INC.	+6.64%	14.03B
SAREPTA THERAPEUTICS, INC.	+31.84%	12.13B

Bio Therapeutic Drugs